Dendreon Corporation
Seattle, WA United States
(NASDAQ: DNDN)

Company Description

Dendreon wants to boost your immunity from the start. It is developing therapeutic vaccines that help the body's immune system fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. Its sole commercial product, Provenge, is a therapeutic vaccine that targets prostate cancer. Provenge gained the status of being the first therapeutic cancer vaccine to receive FDA approval in 2010. Dendreon is also working on a therapeutic vaccine to treat breast, bladder, and ovarian cancers, and it has research programs investigating cancer-fighting monoclonal antibodies and small molecule drugs.

3005 1st Ave.	Phone: 206-256-4545	http://www.dendreon.com
Seattle, WA 98121	Fax: 206-256-0571	Map This Company
United States

Try a Full Premium Subscription

Access over 85 million companies
Call (866) 443-3939 or

Dendreon Corporation Rankings

Executives

249 executives listed for Dendreon Corporation's Seattle, WA location.
Chairman	Richard Brewer	E-mail
President, CEO, and Director	Mitchell Gold	E-mail
EVP and CFO	Gregory Schiffman	E-mail

More Dendreon Corporation Executives

Financials

Company Type	Public - NASDAQ: DNDN Headquarters
Fiscal Year-End	December
2011 Employees	1,475

More Dendreon Corporation Financials

DNBi

Leverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Dendreon Corporation now.

Reduce risk.
Drive greater profitability.
Increase cash flow.

Dendreon CorporationSeattle, WA United States (NASDAQ: DNDN)